266 related articles for article (PubMed ID: 26041469)
1. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the cost effectiveness of herpes zoster vaccination.
Szucs TD; Pfeil AM
Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
van Hoek AJ; Melegaro A; Gay N; Bilcke J; Edmunds WJ
Vaccine; 2012 Feb; 30(6):1225-34. PubMed ID: 22119592
[TBL] [Abstract][Full Text] [Related]
6. Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
van Lier A; Lugnér A; Opstelten W; Jochemsen P; Wallinga J; Schellevis F; Sanders E; de Melker H; van Boven M
EBioMedicine; 2015 Oct; 2(10):1494-9. PubMed ID: 26629544
[TBL] [Abstract][Full Text] [Related]
7. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?
Bilcke J; van Hoek AJ; Beutels P
Hum Vaccin Immunother; 2013 Apr; 9(4):812-22. PubMed ID: 23321955
[TBL] [Abstract][Full Text] [Related]
8. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.
Melegaro A; Marziano V; Del Fava E; Poletti P; Tirani M; Rizzo C; Merler S
BMC Med; 2018 Jul; 16(1):117. PubMed ID: 30012132
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
10. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
[TBL] [Abstract][Full Text] [Related]
11. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
[TBL] [Abstract][Full Text] [Related]
12. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data.
Goldman GS; King PG
Vaccine; 2013 Mar; 31(13):1680-94. PubMed ID: 22659447
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
[TBL] [Abstract][Full Text] [Related]
15. The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.
Sauboin C; Holl K; Bonanni P; Gershon AA; Benninghoff B; Carryn S; Burgess MA; Wutzler P
BMC Infect Dis; 2019 Feb; 19(1):126. PubMed ID: 30727971
[TBL] [Abstract][Full Text] [Related]
16. Herpes zoster in the context of varicella vaccination - An equation with several variables.
Wutzler P; Casabona G; Cnops J; Akpo EIH; Safadi MAP
Vaccine; 2018 Nov; 36(46):7072-7082. PubMed ID: 30309745
[TBL] [Abstract][Full Text] [Related]
17. Modelling varicella vaccination - What does a lack of surge in herpes zoster incidence tell us about exogenous boosting?
Widgren K; Tomba GS; Leung KY; Giesecke J
Vaccine; 2022 Jan; 40(4):673-681. PubMed ID: 34930603
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
[TBL] [Abstract][Full Text] [Related]
19. Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data.
Goldman GS; King PG
Hum Exp Toxicol; 2014 Aug; 33(8):886-93. PubMed ID: 24275643
[TBL] [Abstract][Full Text] [Related]
20. Varicella vaccination in England and Wales: cost-utility analysis.
Brisson M; Edmunds WJ
Arch Dis Child; 2003 Oct; 88(10):862-9. PubMed ID: 14500303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]